Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myelogenous Leukemia
Juvaris wins innovation research grant for acute myelogenous leukemia vaccine development
October 25th, 2006
Juvaris BioTherapeutics, Inc., announced award of a 1-year phase I small business innovation research (SBIR) grant from the U.S. National Cancer Institute (NCI) of the U.S. National Institutes of Health in collaboration with Dr. David Claxton at Pennsylvania State College of Medicine, Pennsylvania State University's medical school, for the development of a therapeutic vaccine approach for the treatment of acute myelogenous leukemia (AML). Juvaris' vaccine technology will be tested in rodent tumor models to evaluate the impact on leukemia using an antigen-specific immunotherapeutic AML vaccine (JuvaVax). The SBIR grant application was supported by preclinical data...
Source: Biotech Week (2006-10-25)
|
